Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 8/2003

01-04-2003 | Leading Article

Nonsteroidal Anti-Inflammatory Drug Use and the Risk for Alzheimer’s Disease

Dissecting the Epidemiological Evidence

Author: Dr Lenore J. Launer

Published in: Drugs | Issue 8/2003

Login to get access

Abstract

Inflammation is hypothesised to contribute to the genesis of pathology causing or contributing to Alzheimer’s disease (AD). As a part of the immune response in the brain, the prostaglandin pathway is induced; this pathway is the target for NSAIDs, the most widely used antiinflammatory medication. There are many epidemiological studies, which are reviewed here, suggesting NSAIDs reduce the risk for AD. The most recent of these studies suggest NSAIDs should be taken for at least 2 years. There are little data in humans about whether one type of NSAID is more effective than another. To date, randomised, double-blind, clinical trials in patients with AD have been negative. There is one prevention trial that will yield valuable information about the efficacy of NSAIDs in slowing down the progression of, or preventing, AD. At present, no recommendations can be made concerning the when, what, who and for how long a person should take an NSAID to reduce his or her risk for AD.
Literature
1.
Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurology 2000; 54 Suppl. 5: S4–9PubMed
2.
Launer LJ, Andersen K, Dewey ME, et al. Rates and risk factors for dementia and Alzheimer’s disease: results from EURODEM pooled analyses. Neurology 1999; 52: 78–84PubMedCrossRef
3.
McKahnn G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–44CrossRef
4.
Selkoe DJ. Toward a comprehensive theory for Alzheimer’s disease. Hypothesis: Alzheimer’s disease is caused by the cerebral accumulation and cytotoxicity of amyloid β-protein. Ann N Y Acad Sci 2000; 924: 7–25
5.
McGeer PL, Itagaki S, Tago H, et al. Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR. Neurosci Let 1987; 79: 195–200CrossRef
6.
Willard LB, Hauss-Wegrzyniak B, Danysz W, et al. The cytotoxicity of chronic neuroinflammation upon basel fore-brain cholineric neurons of rats can be attenuated by glutamatergic antagoinsim or cyclooxygenase-2 inhibition. Exp Brain Res 2000; 134: 58–65PubMedCrossRef
7.
Hensley K, Robinson KA, Gabbita SP, et al. Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med 2000; 28: 1456–62PubMedCrossRef
8.
McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer’s disease. Neurobiol Aging 2001; 22: 799–809PubMedCrossRef
9.
Nicoll JA, Mrak RE, Graham DI, et al. Association of interleukin-1 gene polymorphisms with Alzheimer’s disease. Ann Neurol 2000; 47: 365–8PubMedCrossRef
10.
Benveniste EN. Inflammatory cytokines within the central nervous system: sources, function, and mechanism of action. Am J Physiology 1992; 263 (1 Pt 1): C1–C16
11.
Barger SW, Harmon AD. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 1997; 388: 878–81PubMedCrossRef
12.
Blasko I, Marx F, Steiner E, et al. TNFalpha plus IFNgamma induce the production of Alzheimer beta-amyloid peptides and decrease the production of APPs. FASEB J 1999; 13: 63–8PubMed
13.
Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 8; 400(6740): 173–7PubMedCrossRef
14.
Poduslo JF, Curran GL. Amyloid β peptide as a vaccine for Alzheimer’s disease involves receptor-mediated transport at the blood-brian barrier. Neuroreport 2001; 12: 3197–200PubMedCrossRef
15.
Koistinaho M, Kettunen MI, Goldsteins G, et al. β-amyloid precursor protein transgenic mice that harbor diffuse Aβ deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Natl Acad Sci U S A 2002; 99: 1610–5PubMedCrossRef
16.
17.
Yermakova AV, Rollins J, Callahan LM, et al. Cyclooxygenase-1 in human Alzheimer and control brain: quantitative analysis of expression by microglia and CA3 hippocampal neurons. J Neuropathol Exp Neurol 1999; 58: 1135–46PubMedCrossRef
18.
Hoozemans JJ, Rozemuller AJ, Janssen I, et al. Cyclooxygenase expression in microglia and neurons in Alzheimer’s disease and control brain. Acta Neuropathol (Berl) 2001; 101: 2–8
19.
Delves PJ, Roitt IM, editors. Encyclopedia of immunology. 2nd ed. New York: Academic Press, 1998
20.
Kelley KA, Ho L, Winger D, et al. Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am J Pathol 1999; 155: 995–1004PubMedCrossRef
21.
Bezzi P, Carmignoto G, Pasti L, et al. Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 1998; 391: 281–5PubMedCrossRef
22.
Fiebich BL, Lieb K, Hull M, et al. Effects of NSAIDs on IL-1β-induced IL-6 mRNA and protein synthesis in human astrocytoma cells. Neuroreport 1996; 7: 1209–13PubMedCrossRef
23.
Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J Neurosci 2000; 20: 5709–14PubMed
24.
Blasko I, Apochal A, Boeck G, et al. Ibuprofen decreases cytokine-induced amyloid beta production in neuronal cells. Neurobiol Dis 2001; 8: 1094–101PubMedCrossRef
25.
Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidgenic Aβ42 independently of cyclooxygenase activity. Nature 2001; 414: 212–6PubMedCrossRef
26.
Oviedo JA, Wolfe MM. Clinical potential of cyclo-oxygenase-2 inhibitors. BioDrugs 2001; 15: 563–72PubMedCrossRef
27.
Asanuma M, Nishibayashi-Asanuma S, Miyazaki I, et al. Neurochem neuroprotective effects of non-steroidal antiinflammatory drugs by direct scavenging of nitric oxide radicals. J Neurochem 2001; 76: 1895–904PubMedCrossRef
28.
Jaradat MS, Wongsud B, Phornchirasilp S, et al. Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H(2) synthases by ibuprofen, naproxen, and indomethacin. Biochem Pharmacol 2001; 62: 1587–95PubMedCrossRef
29.
Fenner H. Comparative biochemical pharmacology of the oxicams. Scand J Rheumatol Suppl 1987; 65: 97–101PubMedCrossRef
30.
De Luigi A, Fragiacomo C, Lucca U, et al. Inflammatory markers in Alzheimer’s disease and multi-infarct dementia. Mech Ageing Dev 2001; 122: 1985–95PubMedCrossRef
31.
Monsonego A, Maron R, Zota V, et al. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer’s disease. Proc Natl Acad Sci U S A 2001; 98: 10273–8PubMedCrossRef
32.
Schmidt R, Schmidt H, Curb JD, et al. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia aging study. Ann Neurol 2002; 52: 168–74PubMedCrossRef
33.
Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer’s disease in Australia. Neurology 1990; 40: 1698–707PubMedCrossRef
34.
French LR, Schuman LM, Mortimer JA, et al. A case-control study of dementia of the Alzheimer’s type. Am J Epidemiol 1985; 121: 414–21PubMed
35.
Heyman A, Wilkinson WE, Stafford JA, et al. Alzheimer’s disease: a study of epidemiological aspects. Ann Neurology 1984; 15: 335–41CrossRef
36.
Graves AB, White E, Koepsell TD, et al. A case-control study of Alzheimer’s disease. Ann Neurol 1990; 28: 766–74PubMedCrossRef
37.
Myllykangas-Luosujarvi R, Isomaki H. Alzheimer’s disease and rheumatoid arthritis [letter]. Br J Rheumatol 1994; 33: 501–2PubMedCrossRef
38.
Henderson AS, Jorm AF, Korten AE, et al. Environmental risk factors for Alzheimer’s disease: their relationship to age of onset and to familial or sporadic types. Psychol Med 1992; 22: 429–36PubMedCrossRef
39.
Amaducci LA, Fratiglioni F, Rocca WA, et al. Risk factors for clinically diagnosed Alzheimer’s disease: a case-control study of an Italian population. Neurology 1986; 36: 922–31PubMedCrossRef
40.
Kukull WA, Larson EB, Stergachis A, et al. Nonsteroidal antiinflammtory drug use and risk of Alzheimer’s disease [abstract]. Neurology 1994; 44 Suppl. 2: A237
41.
Breitner JC, Gau BA, Welsh KA, et al. Inverse association of antiinflammatory treatments and Alzheimer’s disease: initial results of a co-twin control study. Neurology 1994; 44: 227–32PubMedCrossRef
42.
Breitner JCS, Welsh KA, Helms MJ, et al. Delayed onset of Alzheimer’s disease with nonsteroidal antiinflammatory and histamine H2 blocking drugs. Neurobiol Aging 1995; 16: 523–30PubMedCrossRef
43.
Anthony JC, Breitner JC, Zandi PP, et al. Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists: the Cache County study. Neurology 2000; 54: 2066–71PubMedCrossRef
44.
Canadian Study of Health and Aging. The Canadian Study of Health and Aging: risk factors for Alzheimer’s disease in Canada. Neurology 1994; 44: 2073–80CrossRef
45.
Beard CM, Waring SC, O’Brien PC, et al. Nonsteroidal antiinflammatory drug use and Alzheimer’s disease: a case control study in Rochester, Minnesota, 1980 through 1984. Mayo Clin Proc 1998; 73: 951–5PubMedCrossRef
46.
Andersen K, Launer LJ, Ott A, et al. Do nonsteroidal antiinflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study. Neurology 1995; 45: 441–5CrossRef
47.
Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research methods. New York: Van Nostrand Reinhold Company, 1982
48.
Lasky T, Stolley PD. Selection of cases and control. Epidemiol Rev 1994; 16: 6–17PubMed
49.
Hoes AW, Grobbee DE, Lubsen J. Primary prevention in hypertension: valid conclusions from observational studies. Circulation 1991; 84 (6 Suppl.): VI78–83PubMed
50.
Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997; 48: 626–32PubMedCrossRef
51.
In’t Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 2001; 345: 1515–21CrossRef
52.
Sainaili SM, Ingram DM, Talwaker S. Results of a double-blind placebo controlled study of celecoxib for the progression of Alzheimer’s disease. 6th International Stockholm-Springfield Symposium in Alzheimer’s Disease Therapy; 2000 Apr 5–8; Stockholm
53.
Aisen PS, Schmeidler J, Pasinetti GM. Randomized pilot study of nimesulide treatment in Alzheimer’s disease. Neurology 2002; 58: 1050–4PubMedCrossRef
54.
Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer’s disease. Alzheimer’s Disease Cooperative Study. Neurology 2000; 54: 588–93
55.
Scharf S, Mander A, Ugoni A, et al. A double-blind, placebocontrolled trial of diclofenac/misoprostol in Alzheimer’s disease. Neurology 1999; 53: 197–201PubMedCrossRef
56.
Van Gool WA, Weinstein HC, Scheltens P, et al. Effect of hydroxychloroquine on progression of dementia in early Alzheimer’s disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet 2001; 358: 455–60PubMedCrossRef
57.
Aisen PS. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer’s disease. J Pain Symptom Manage 2002; 23 (4 Suppl.): S35–40PubMedCrossRef
58.
59.
Martin BK, Meinert CL, Breitner JC, et al. Double placebo design in a prevention trial for Alzheimer’s disease. Control Clin Trials 2002; 23: 93–9PubMedCrossRef
Metadata
Title
Nonsteroidal Anti-Inflammatory Drug Use and the Risk for Alzheimer’s Disease
Dissecting the Epidemiological Evidence
Author
Dr Lenore J. Launer
Publication date
01-04-2003
Publisher
Springer International Publishing
Published in
Drugs / Issue 8/2003
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200363080-00001

Other articles of this Issue 8/2003

Drugs 8/2003 Go to the issue

Leading Article

Therapeutic Drug Monitoring

Adis Drug Evaluation

Lopinavir/Ritonavir

Adis Drug Evaluation

Rituximab

Therapy In Practice

Postoperative Analgesia and Sedation in the Adult Intensive Care Unit